Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595

ABSTRACT Introduction: Glaucoma refers to a heterogeneous group of optic neuropathies characterized by an enhanced intraocular pressure (IOP). To date, there are six available different drug classes for the treatment of glaucoma and ocular hypertension: β-adrenergic antagonists, prostaglandins, carbonic anhydrase inhibitors, α2-selective adrenergic, muscarinic agonists and rho kinase inhibitors, which act by reducing the production or increasing the drainage of aqueous humor. Areas covered: This manuscript reviews patent US2018244666A1, that describes the synthesis of novel potential rho kinase and monoamine transporters inhibitors with a benzamide or isoquinoline amide scaffolds, and patent US2018256595A1 that investigates the long-term treatment of glaucoma or ocular hypertension with ripasudil, a rho kinase inhibitor. Expert opinion: A variety of netarsudil congeners were synthesized as rho kinases inhibitors in patent US2018244666A1. Results of patent US2018256595A1 showed that ripasudil is among the best candidates for glaucoma long-term treatment, as IOP continuously dropped over the course of the treatment.

• Publication year

  2019

• Venue

  Expert Opinion on Therapeutic Patents

• Publication date

  2019-08-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/13543776.2019.1658743PMID 31438732
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life

  2019cited by this paper
• Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication.

  2019cited by this paper
• Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination

  2019cited by this paper
• Glaucoma: Current treatment and impact of advanced drug delivery systems

  2019cited by this paper
• Cholinergic nervous system and glaucoma: From basic science to clinical applications.

  2019cited by this paper
• Does using topical latanoprost affect subfoveal choroidal thickness?

  2019cited by this paper
• Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.

  2018cited by this paper
• Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

  2018cited by this paper
• Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)

  2017cited by this paper
• One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy

  2017cited by this paper
• Glaucoma treatment trends: a review.

  2017cited by this paper
• Primary congenital and developmental glaucomas

  2017cited by this paper
• Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy

  2016cited by this paper
• Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy

  2016cited by this paper
• Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.

  2016cited by this paper
• Effect of alpha-2-agonist premedication on intraocular pressure after selective laser trabeculoplasty

  2015cited by this paper
• Preparation and Evaluation of Chitosan Submicroparticles Containing Pilocarpine for Glaucoma Therapy.

  2015cited by this paper
• The pathophysiology and treatment of glaucoma: a review.

  2014cited by this paper
• Glaucoma and the applications of carbonic anhydrase inhibitors.

  2014cited by this paper
• Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets.

  2010cited by this paper
• Primary open-angle glaucoma.

  2009cited by this paper
• Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

  2008cited by this paper
• Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery

  2005cited by this paper
• Biogenic amine neurotransmitter transporters: just when you thought you knew them.

  2005cited by this paper
• Carbonic anhydrase inhibitors

  2003cited by this paper
• Ocular Perfusion Pressure and Visual Field Indice Modifications Induced by α-Agonist Compound (Clonidine 0.125%, Apraclonidine 1.0% and Brimonidine 0.2%) Topical Administration

  2003cited by this paper
• Carbonic anhydrase inhibitors.

  2003cited by this paper
• Carbonic anhydrase inhibitors and their therapeutic potential

  2000cited by this paper
• Derivatives of 17-phenyl-18,19,20-trinorprostaglandin F2 alpha isopropyl ester: potential antiglaucoma agents.

  1995cited by this paper
• Turnover of total carbon dioxide in the aqueous humors and the effect thereon of acetazolamide.

  1959cited by this paper
• The mechanism of the fall in intraocular pressure induced by the carbonic anhydrase inhibitor, diamox.

  1955cited by this paper

• Rho GTPase and Rho Kinase Signaling in Tissue Contractility and Intraocular Pressure Regulation.

  2026cites this paper
• HPLC-DAD method for concurrent estimation of netarsudil, latanoprost and benzalkonium chloride: Stability indicating study, impurity separation, assay of ophthalmic preparations and greenness/whiteness valuation

  2024cites this paper
• Interventional glaucoma and the patient perspective

  2024cites this paper
• ROCK inhibitor: Focus on recent updates

  2023cites this paper
• The management of glaucoma and macular degeneration

  2019cites this paper